This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
In this edition of STAT's Health Tech newsletter: Why Clear wants to get into th...
TUESDAY, April 8, 2025 -- Blue laser vaporization alleviates lower urinary trac...
TUESDAY, April 8, 2025 -- For patients with diabetes, semaglutide use is associ...
TUESDAY, April 8, 2025 -- One in 13 youth and adolescents globally experience n...
TUESDAY, April 8, 2025 -- Narrowband UVB (nbUVB) phototherapy may be underutili...
TUESDAY, April 8, 2025 -- A mobile health (mHealth)-supported home-delivered ph...
TUESDAY, April 8, 2025 -- There are substantial rural-urban disparities in card...
TUESDAY, April 8, 2025 -- For patients with Parkinson disease with motor fluctu...
TUESDAY, April 8, 2025 -- The U.S. Preventive Services Task Force (USPSTF) reco...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
“There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrot...
This week in health care policy and politics: RFK Jr.'s hearing delayed, measles...
The company has decided to switch gears following disappointing data for a monoc...
Prapela’s device provides gentle, randomized movements that aim to trigger and r...
The company has decided to switch gears following disappointing data for a monoc...
Human medicines European public assessment report (EPAR): Loqtorzi, Toripalimab,...
As the countdown to the launch of its first therapeutic continues, Rocket Pharma...
The HHS secretary called out the measles vaccines as "the most effective way" to...
Human medicines European public assessment report (EPAR): Kentera (previously Ox...
Human medicines European public assessment report (EPAR): Azilect, rasagiline, D...
A U.S. congressional commission has made the case for “swift action” to maintain...
Editor's note: This story contains a description of self-harm. Oncologist Mark L...
EMA roundtable with stakeholders on the 20th anniversary of the SME Regulation, ...
Johnson & Johnson has reinforced a key plank of its plan to build nipocalimab in...